National Institutes of Health
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) is a funding opportunity from National Institutes of Health, closing January 7, 2028.
Overview
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality,…